[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fHUOFuvb6JhbVf8zepVUts8BWe5cyvsndsYU0f-fbwQc":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":9,"nonDrugCount":11,"topConditions":12,"upcomingReadouts":31,"phaseBuckets":37,"rows":44},"University of Kentucky",[4],69,false,7,2,100188,50,[13,16,19,21,23,25,27,29],{"name":14,"count":15},"Obesity",4,{"name":17,"count":18},"Breast Cancer",3,{"name":20,"count":18},"Cocaine Use Disorder",{"name":22,"count":18},"Stroke",{"name":24,"count":9},"Healthy",{"name":26,"count":9},"Prostate Cancer",{"name":28,"count":9},"Cocaine Dependence",{"name":30,"count":9},"Asthma",[32],{"nctId":33,"briefTitle":34,"date":35,"intervention":36},"NCT05729932","Cannabis and Opioid Use Disorder","2027-06-30","Inhaled vaporized cannabis",[38,39,40,41,42,43],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[45,70,88,136,154,172,190,225,243,268,286,304,322,340,358,393,429,453,479,497,521,546,564,601,619,637,655,673,691,709,727,745,763,781,799,817,835,863,888,906,924,948,973],{"intervention":36,"totalTrials":46,"cells":47},1,{"EARLY_PHASE1":48,"PHASE1":51,"PHASE2":62,"PHASE3":64,"PHASE4":66,"NA":68},{"trials":49,"activeCount":50},[],0,{"trials":52,"activeCount":46,"soonestReadout":35},[53],{"nctId":33,"briefTitle":34,"status":54,"phases":55,"primaryCompletion":35,"completion":35,"start":56,"enrollment":57,"conditions":58,"interventions":60},"RECRUITING",[39],"2024-09-10",15,[59],"Opioid Use Disorder",[36,61],"Intransal opioid",{"trials":63,"activeCount":50},[],{"trials":65,"activeCount":50},[],{"trials":67,"activeCount":50},[],{"trials":69,"activeCount":50},[],{"intervention":61,"totalTrials":46,"cells":71},{"EARLY_PHASE1":72,"PHASE1":74,"PHASE2":80,"PHASE3":82,"PHASE4":84,"NA":86},{"trials":73,"activeCount":50},[],{"trials":75,"activeCount":46,"soonestReadout":35},[76],{"nctId":33,"briefTitle":34,"status":54,"phases":77,"primaryCompletion":35,"completion":35,"start":56,"enrollment":57,"conditions":78,"interventions":79},[39],[59],[36,61],{"trials":81,"activeCount":50},[],{"trials":83,"activeCount":50},[],{"trials":85,"activeCount":50},[],{"trials":87,"activeCount":50},[],{"intervention":89,"totalTrials":9,"cells":90},"filgrastim",{"EARLY_PHASE1":91,"PHASE1":93,"PHASE2":95,"PHASE3":116,"PHASE4":132,"NA":134},{"trials":92,"activeCount":50},[],{"trials":94,"activeCount":50},[],{"trials":96,"activeCount":50},[97],{"nctId":98,"briefTitle":99,"status":100,"phases":101,"primaryCompletion":102,"start":103,"enrollment":104,"conditions":105,"interventions":112},"NCT00003425","Phase I\u002FII Study of Escalating-Dose Melphalan w\u002FAutologous SCS & Amifostine Cytoprotect","COMPLETED",[39,40],"2002-07","1997-12",25,[17,106,107,108,109,110,111],"Leukemia","Lymphoma","Neuroblastoma","Ovarian Cancer","Sarcoma","Unspecified Adult Solid Tumor, Protocol Specific",[89,113,114,115],"amifostine trihydrate","cyclophosphamide","melphalan",{"trials":117,"activeCount":50},[118],{"nctId":119,"briefTitle":120,"status":121,"phases":122,"primaryCompletion":123,"completion":123,"start":124,"enrollment":125,"conditions":126,"interventions":128},"NCT00237575","Randomized Phase III Trial of Leukine® vs Neupogen® in Patients Receiving Cisplatin & Gemcitabine for Urothelial Cancer","TERMINATED",[41],"2006-03","2005-11",100,[127],"Bladder Cancer",[129,130,131,89],"gemcitabine","cisplatin","sargramostim",{"trials":133,"activeCount":50},[],{"trials":135,"activeCount":50},[],{"intervention":129,"totalTrials":46,"cells":137},{"EARLY_PHASE1":138,"PHASE1":140,"PHASE2":142,"PHASE3":144,"PHASE4":150,"NA":152},{"trials":139,"activeCount":50},[],{"trials":141,"activeCount":50},[],{"trials":143,"activeCount":50},[],{"trials":145,"activeCount":50},[146],{"nctId":119,"briefTitle":120,"status":121,"phases":147,"primaryCompletion":123,"completion":123,"start":124,"enrollment":125,"conditions":148,"interventions":149},[41],[127],[129,130,131,89],{"trials":151,"activeCount":50},[],{"trials":153,"activeCount":50},[],{"intervention":130,"totalTrials":46,"cells":155},{"EARLY_PHASE1":156,"PHASE1":158,"PHASE2":160,"PHASE3":162,"PHASE4":168,"NA":170},{"trials":157,"activeCount":50},[],{"trials":159,"activeCount":50},[],{"trials":161,"activeCount":50},[],{"trials":163,"activeCount":50},[164],{"nctId":119,"briefTitle":120,"status":121,"phases":165,"primaryCompletion":123,"completion":123,"start":124,"enrollment":125,"conditions":166,"interventions":167},[41],[127],[129,130,131,89],{"trials":169,"activeCount":50},[],{"trials":171,"activeCount":50},[],{"intervention":131,"totalTrials":46,"cells":173},{"EARLY_PHASE1":174,"PHASE1":176,"PHASE2":178,"PHASE3":180,"PHASE4":186,"NA":188},{"trials":175,"activeCount":50},[],{"trials":177,"activeCount":50},[],{"trials":179,"activeCount":50},[],{"trials":181,"activeCount":50},[182],{"nctId":119,"briefTitle":120,"status":121,"phases":183,"primaryCompletion":123,"completion":123,"start":124,"enrollment":125,"conditions":184,"interventions":185},[41],[127],[129,130,131,89],{"trials":187,"activeCount":50},[],{"trials":189,"activeCount":50},[],{"intervention":191,"totalTrials":9,"cells":192},"dexamethasone",{"EARLY_PHASE1":193,"PHASE1":195,"PHASE2":197,"PHASE3":219,"PHASE4":221,"NA":223},{"trials":194,"activeCount":50},[],{"trials":196,"activeCount":50},[],{"trials":198,"activeCount":50},[199,208],{"nctId":200,"briefTitle":201,"status":121,"phases":202,"primaryCompletion":203,"completion":203,"start":204,"enrollment":9,"conditions":205,"interventions":206},"NCT00176293","Randomized Phase II Trial of Doxil With or Without Dexamethasone for Metastatic Hormone Refractory Prostate Cancer",[40],"2007-02","2005-10",[26],[191,207],"doxorubicin",{"nctId":209,"briefTitle":210,"status":211,"phases":212,"start":213,"enrollment":50,"conditions":214,"interventions":216},"NCT00176280","Randomized Phase 2 Trial of Pre-chemotherapy Leukine vs. Leukine-Dexamethasone in Combination With Gemzar & 5-FU in Patients With Metastatic Renal Cell Carcinoma","WITHDRAWN",[40],"2005-09",[215],"Renal Cell Carcinoma",[217,218],"Leukine","Dexamethasone",{"trials":220,"activeCount":50},[],{"trials":222,"activeCount":50},[],{"trials":224,"activeCount":50},[],{"intervention":207,"totalTrials":46,"cells":226},{"EARLY_PHASE1":227,"PHASE1":229,"PHASE2":231,"PHASE3":237,"PHASE4":239,"NA":241},{"trials":228,"activeCount":50},[],{"trials":230,"activeCount":50},[],{"trials":232,"activeCount":50},[233],{"nctId":200,"briefTitle":201,"status":121,"phases":234,"primaryCompletion":203,"completion":203,"start":204,"enrollment":9,"conditions":235,"interventions":236},[40],[26],[191,207],{"trials":238,"activeCount":50},[],{"trials":240,"activeCount":50},[],{"trials":242,"activeCount":50},[],{"intervention":244,"totalTrials":46,"cells":245},"Bendamustine",{"EARLY_PHASE1":246,"PHASE1":248,"PHASE2":250,"PHASE3":262,"PHASE4":264,"NA":266},{"trials":247,"activeCount":50},[],{"trials":249,"activeCount":50},[],{"trials":251,"activeCount":50},[252],{"nctId":253,"briefTitle":254,"status":211,"phases":255,"primaryCompletion":256,"completion":256,"start":257,"enrollment":50,"conditions":258,"interventions":260},"NCT00758693","Frontline Treatment With Bendamustine in Combination With Rituximab in Adults Age 65 or Older With Chronic Lymphocytic Leukemia (CLL)",[40],"2010-07","2008-10",[259],"Chronic Lymphocytic Leukemia",[244,261],"Rituximab",{"trials":263,"activeCount":50},[],{"trials":265,"activeCount":50},[],{"trials":267,"activeCount":50},[],{"intervention":261,"totalTrials":46,"cells":269},{"EARLY_PHASE1":270,"PHASE1":272,"PHASE2":274,"PHASE3":280,"PHASE4":282,"NA":284},{"trials":271,"activeCount":50},[],{"trials":273,"activeCount":50},[],{"trials":275,"activeCount":50},[276],{"nctId":253,"briefTitle":254,"status":211,"phases":277,"primaryCompletion":256,"completion":256,"start":257,"enrollment":50,"conditions":278,"interventions":279},[40],[259],[244,261],{"trials":281,"activeCount":50},[],{"trials":283,"activeCount":50},[],{"trials":285,"activeCount":50},[],{"intervention":217,"totalTrials":46,"cells":287},{"EARLY_PHASE1":288,"PHASE1":290,"PHASE2":292,"PHASE3":298,"PHASE4":300,"NA":302},{"trials":289,"activeCount":50},[],{"trials":291,"activeCount":50},[],{"trials":293,"activeCount":50},[294],{"nctId":209,"briefTitle":210,"status":211,"phases":295,"start":213,"enrollment":50,"conditions":296,"interventions":297},[40],[215],[217,218],{"trials":299,"activeCount":50},[],{"trials":301,"activeCount":50},[],{"trials":303,"activeCount":50},[],{"intervention":113,"totalTrials":46,"cells":305},{"EARLY_PHASE1":306,"PHASE1":308,"PHASE2":310,"PHASE3":316,"PHASE4":318,"NA":320},{"trials":307,"activeCount":50},[],{"trials":309,"activeCount":50},[],{"trials":311,"activeCount":50},[312],{"nctId":98,"briefTitle":99,"status":100,"phases":313,"primaryCompletion":102,"start":103,"enrollment":104,"conditions":314,"interventions":315},[39,40],[17,106,107,108,109,110,111],[89,113,114,115],{"trials":317,"activeCount":50},[],{"trials":319,"activeCount":50},[],{"trials":321,"activeCount":50},[],{"intervention":114,"totalTrials":46,"cells":323},{"EARLY_PHASE1":324,"PHASE1":326,"PHASE2":328,"PHASE3":334,"PHASE4":336,"NA":338},{"trials":325,"activeCount":50},[],{"trials":327,"activeCount":50},[],{"trials":329,"activeCount":50},[330],{"nctId":98,"briefTitle":99,"status":100,"phases":331,"primaryCompletion":102,"start":103,"enrollment":104,"conditions":332,"interventions":333},[39,40],[17,106,107,108,109,110,111],[89,113,114,115],{"trials":335,"activeCount":50},[],{"trials":337,"activeCount":50},[],{"trials":339,"activeCount":50},[],{"intervention":115,"totalTrials":46,"cells":341},{"EARLY_PHASE1":342,"PHASE1":344,"PHASE2":346,"PHASE3":352,"PHASE4":354,"NA":356},{"trials":343,"activeCount":50},[],{"trials":345,"activeCount":50},[],{"trials":347,"activeCount":50},[348],{"nctId":98,"briefTitle":99,"status":100,"phases":349,"primaryCompletion":102,"start":103,"enrollment":104,"conditions":350,"interventions":351},[39,40],[17,106,107,108,109,110,111],[89,113,114,115],{"trials":353,"activeCount":50},[],{"trials":355,"activeCount":50},[],{"trials":357,"activeCount":50},[],{"intervention":359,"totalTrials":9,"cells":360},"Methamphetamine",{"EARLY_PHASE1":361,"PHASE1":374,"PHASE2":385,"PHASE3":387,"PHASE4":389,"NA":391},{"trials":362,"activeCount":50},[363],{"nctId":364,"briefTitle":365,"status":100,"phases":366,"primaryCompletion":367,"completion":367,"start":368,"enrollment":369,"conditions":370,"interventions":373},"NCT01967381","Targeting GABA and Opioid Systems for a Pharmacotherapy for Methamphetamine Abuse",[38],"2018-09","2013-10",24,[371,372],"Methamphetamine Abuse","Methamphetamine Dependence",[359],{"trials":375,"activeCount":50},[376],{"nctId":377,"briefTitle":378,"status":100,"phases":379,"primaryCompletion":380,"completion":380,"start":381,"enrollment":382,"conditions":383,"interventions":384},"NCT01843205","Buspirone as a Candidate Medication for Methamphetamine Abuse",[39],"2017-03","2013-04",9,[372,371],[359],{"trials":386,"activeCount":50},[],{"trials":388,"activeCount":50},[],{"trials":390,"activeCount":50},[],{"trials":392,"activeCount":50},[],{"intervention":394,"totalTrials":9,"cells":395},"Cocaine",{"EARLY_PHASE1":396,"PHASE1":408,"PHASE2":421,"PHASE3":423,"PHASE4":425,"NA":427},{"trials":397,"activeCount":50},[398],{"nctId":399,"briefTitle":400,"status":100,"phases":401,"primaryCompletion":402,"completion":402,"start":403,"enrollment":57,"conditions":404,"interventions":406},"NCT02141620","n-Acetylcysteine and Cocaine",[38],"2016-04","2014-05",[405,28],"Cocaine Abuse",[394,407],"n-Acetylcysteine",{"trials":409,"activeCount":50},[410],{"nctId":411,"briefTitle":412,"status":100,"phases":413,"primaryCompletion":414,"completion":414,"start":415,"enrollment":416,"conditions":417,"interventions":418},"NCT02239913","Topiramate-Phentermine Combinations for Cocaine Dependence",[39],"2019-09","2014-09",38,[20],[394,419,420],"Phentermine","Topiramate",{"trials":422,"activeCount":50},[],{"trials":424,"activeCount":50},[],{"trials":426,"activeCount":50},[],{"trials":428,"activeCount":50},[],{"intervention":430,"totalTrials":46,"cells":431},"d-Amphetamine; Atomoxetine",{"EARLY_PHASE1":432,"PHASE1":434,"PHASE2":445,"PHASE3":447,"PHASE4":449,"NA":451},{"trials":433,"activeCount":50},[],{"trials":435,"activeCount":50},[436],{"nctId":437,"briefTitle":438,"status":100,"phases":439,"primaryCompletion":440,"completion":440,"start":441,"enrollment":442,"conditions":443,"interventions":444},"NCT00697138","Agonist Replacement Therapy for Cocaine Dependence",[39],"2012-01","2006-06",46,[28],[430],{"trials":446,"activeCount":50},[],{"trials":448,"activeCount":50},[],{"trials":450,"activeCount":50},[],{"trials":452,"activeCount":50},[],{"intervention":454,"totalTrials":46,"cells":455},"BioXclude amnion-chorion membrane",{"EARLY_PHASE1":456,"PHASE1":458,"PHASE2":471,"PHASE3":473,"PHASE4":475,"NA":477},{"trials":457,"activeCount":50},[],{"trials":459,"activeCount":50},[460],{"nctId":461,"briefTitle":462,"status":100,"phases":463,"primaryCompletion":464,"completion":464,"start":465,"enrollment":466,"conditions":467,"interventions":469},"NCT03422692","Socket Preservation: A Clinical and Histological Study",[39],"2015-10-01","2013-10-01",43,[468],"Alveolar Ridge Augmentations",[454,470],"Mem-Lok collagenous membrane",{"trials":472,"activeCount":50},[],{"trials":474,"activeCount":50},[],{"trials":476,"activeCount":50},[],{"trials":478,"activeCount":50},[],{"intervention":470,"totalTrials":46,"cells":480},{"EARLY_PHASE1":481,"PHASE1":483,"PHASE2":489,"PHASE3":491,"PHASE4":493,"NA":495},{"trials":482,"activeCount":50},[],{"trials":484,"activeCount":50},[485],{"nctId":461,"briefTitle":462,"status":100,"phases":486,"primaryCompletion":464,"completion":464,"start":465,"enrollment":466,"conditions":487,"interventions":488},[39],[468],[454,470],{"trials":490,"activeCount":50},[],{"trials":492,"activeCount":50},[],{"trials":494,"activeCount":50},[],{"trials":496,"activeCount":50},[],{"intervention":498,"totalTrials":46,"cells":499},"7-t-butyldimethylsilyl-10-hydroxycamptothecin",{"EARLY_PHASE1":500,"PHASE1":502,"PHASE2":513,"PHASE3":515,"PHASE4":517,"NA":519},{"trials":501,"activeCount":50},[],{"trials":503,"activeCount":50},[504],{"nctId":505,"briefTitle":506,"status":100,"phases":507,"primaryCompletion":508,"completion":508,"start":509,"enrollment":18,"conditions":510,"interventions":512},"NCT01202370","A Phase I Study of AR-67 (7-t-butyldimethylsilyl-10-hydroxycamptothecin) Given on Days 1, 4 8, 12 & 15 of an Every 21-day Cycle in Adult Patients With Refractory or Metastatic Solid Malignancies",[39],"2011-07","2010-09",[511],"Solid Malignancies",[498],{"trials":514,"activeCount":50},[],{"trials":516,"activeCount":50},[],{"trials":518,"activeCount":50},[],{"trials":520,"activeCount":50},[],{"intervention":522,"totalTrials":46,"cells":523},"Velcade",{"EARLY_PHASE1":524,"PHASE1":526,"PHASE2":538,"PHASE3":540,"PHASE4":542,"NA":544},{"trials":525,"activeCount":50},[],{"trials":527,"activeCount":50},[528],{"nctId":529,"briefTitle":530,"status":100,"phases":531,"primaryCompletion":257,"completion":257,"start":532,"enrollment":533,"conditions":534,"interventions":536},"NCT00382954","Phase I Using Velcade & Idarubicin in Elderly and Relapsed AML",[39],"2004-02",55,[535],"Acute Myelogenous Leukemia",[522,537],"Idarubicin",{"trials":539,"activeCount":50},[],{"trials":541,"activeCount":50},[],{"trials":543,"activeCount":50},[],{"trials":545,"activeCount":50},[],{"intervention":537,"totalTrials":46,"cells":547},{"EARLY_PHASE1":548,"PHASE1":550,"PHASE2":556,"PHASE3":558,"PHASE4":560,"NA":562},{"trials":549,"activeCount":50},[],{"trials":551,"activeCount":50},[552],{"nctId":529,"briefTitle":530,"status":100,"phases":553,"primaryCompletion":257,"completion":257,"start":532,"enrollment":533,"conditions":554,"interventions":555},[39],[535],[522,537],{"trials":557,"activeCount":50},[],{"trials":559,"activeCount":50},[],{"trials":561,"activeCount":50},[],{"trials":563,"activeCount":50},[],{"intervention":565,"totalTrials":46,"cells":566},"High Intensity Counseling + Long Acting NRT + PRN NRT",{"EARLY_PHASE1":567,"PHASE1":569,"PHASE2":593,"PHASE3":595,"PHASE4":597,"NA":599},{"trials":568,"activeCount":50},[],{"trials":570,"activeCount":50},[571],{"nctId":572,"briefTitle":573,"status":100,"phases":574,"primaryCompletion":575,"completion":575,"start":576,"enrollment":577,"conditions":578,"interventions":581},"NCT02048917","Optimization of Smoking Cessation Strategies Concurrent With Treatment of Tobacco Related Malignancies",[39],"2019-05-15","2014-07-22",93,[579,580],"Lung Cancer","Head and Neck Cancer",[565,582,583,584,585,586,587,588,589,590,591,592],"High Intensity Counseling + bupropion + PRN NRT","High Intensity Counseling + varenicline + PRN NRT","High Intensity Counseling + Long Acting NRT","High Intensity Counseling + bupropion","High Intensity Counseling + varenicline","Low Intensity Counseling + Long Acting NRT + PRN NRT","Low Intensity Counseling + bupropion + PRN NRT","Low Intensity Counseling + varenicline + PRN NRT","Low Intensity Counseling + Long Acting NRT","Low Intensity Counseling + bupropion","Low Intensity Counseling + varenicline",{"trials":594,"activeCount":50},[],{"trials":596,"activeCount":50},[],{"trials":598,"activeCount":50},[],{"trials":600,"activeCount":50},[],{"intervention":582,"totalTrials":46,"cells":602},{"EARLY_PHASE1":603,"PHASE1":605,"PHASE2":611,"PHASE3":613,"PHASE4":615,"NA":617},{"trials":604,"activeCount":50},[],{"trials":606,"activeCount":50},[607],{"nctId":572,"briefTitle":573,"status":100,"phases":608,"primaryCompletion":575,"completion":575,"start":576,"enrollment":577,"conditions":609,"interventions":610},[39],[579,580],[565,582,583,584,585,586,587,588,589,590,591,592],{"trials":612,"activeCount":50},[],{"trials":614,"activeCount":50},[],{"trials":616,"activeCount":50},[],{"trials":618,"activeCount":50},[],{"intervention":583,"totalTrials":46,"cells":620},{"EARLY_PHASE1":621,"PHASE1":623,"PHASE2":629,"PHASE3":631,"PHASE4":633,"NA":635},{"trials":622,"activeCount":50},[],{"trials":624,"activeCount":50},[625],{"nctId":572,"briefTitle":573,"status":100,"phases":626,"primaryCompletion":575,"completion":575,"start":576,"enrollment":577,"conditions":627,"interventions":628},[39],[579,580],[565,582,583,584,585,586,587,588,589,590,591,592],{"trials":630,"activeCount":50},[],{"trials":632,"activeCount":50},[],{"trials":634,"activeCount":50},[],{"trials":636,"activeCount":50},[],{"intervention":584,"totalTrials":46,"cells":638},{"EARLY_PHASE1":639,"PHASE1":641,"PHASE2":647,"PHASE3":649,"PHASE4":651,"NA":653},{"trials":640,"activeCount":50},[],{"trials":642,"activeCount":50},[643],{"nctId":572,"briefTitle":573,"status":100,"phases":644,"primaryCompletion":575,"completion":575,"start":576,"enrollment":577,"conditions":645,"interventions":646},[39],[579,580],[565,582,583,584,585,586,587,588,589,590,591,592],{"trials":648,"activeCount":50},[],{"trials":650,"activeCount":50},[],{"trials":652,"activeCount":50},[],{"trials":654,"activeCount":50},[],{"intervention":585,"totalTrials":46,"cells":656},{"EARLY_PHASE1":657,"PHASE1":659,"PHASE2":665,"PHASE3":667,"PHASE4":669,"NA":671},{"trials":658,"activeCount":50},[],{"trials":660,"activeCount":50},[661],{"nctId":572,"briefTitle":573,"status":100,"phases":662,"primaryCompletion":575,"completion":575,"start":576,"enrollment":577,"conditions":663,"interventions":664},[39],[579,580],[565,582,583,584,585,586,587,588,589,590,591,592],{"trials":666,"activeCount":50},[],{"trials":668,"activeCount":50},[],{"trials":670,"activeCount":50},[],{"trials":672,"activeCount":50},[],{"intervention":586,"totalTrials":46,"cells":674},{"EARLY_PHASE1":675,"PHASE1":677,"PHASE2":683,"PHASE3":685,"PHASE4":687,"NA":689},{"trials":676,"activeCount":50},[],{"trials":678,"activeCount":50},[679],{"nctId":572,"briefTitle":573,"status":100,"phases":680,"primaryCompletion":575,"completion":575,"start":576,"enrollment":577,"conditions":681,"interventions":682},[39],[579,580],[565,582,583,584,585,586,587,588,589,590,591,592],{"trials":684,"activeCount":50},[],{"trials":686,"activeCount":50},[],{"trials":688,"activeCount":50},[],{"trials":690,"activeCount":50},[],{"intervention":587,"totalTrials":46,"cells":692},{"EARLY_PHASE1":693,"PHASE1":695,"PHASE2":701,"PHASE3":703,"PHASE4":705,"NA":707},{"trials":694,"activeCount":50},[],{"trials":696,"activeCount":50},[697],{"nctId":572,"briefTitle":573,"status":100,"phases":698,"primaryCompletion":575,"completion":575,"start":576,"enrollment":577,"conditions":699,"interventions":700},[39],[579,580],[565,582,583,584,585,586,587,588,589,590,591,592],{"trials":702,"activeCount":50},[],{"trials":704,"activeCount":50},[],{"trials":706,"activeCount":50},[],{"trials":708,"activeCount":50},[],{"intervention":588,"totalTrials":46,"cells":710},{"EARLY_PHASE1":711,"PHASE1":713,"PHASE2":719,"PHASE3":721,"PHASE4":723,"NA":725},{"trials":712,"activeCount":50},[],{"trials":714,"activeCount":50},[715],{"nctId":572,"briefTitle":573,"status":100,"phases":716,"primaryCompletion":575,"completion":575,"start":576,"enrollment":577,"conditions":717,"interventions":718},[39],[579,580],[565,582,583,584,585,586,587,588,589,590,591,592],{"trials":720,"activeCount":50},[],{"trials":722,"activeCount":50},[],{"trials":724,"activeCount":50},[],{"trials":726,"activeCount":50},[],{"intervention":589,"totalTrials":46,"cells":728},{"EARLY_PHASE1":729,"PHASE1":731,"PHASE2":737,"PHASE3":739,"PHASE4":741,"NA":743},{"trials":730,"activeCount":50},[],{"trials":732,"activeCount":50},[733],{"nctId":572,"briefTitle":573,"status":100,"phases":734,"primaryCompletion":575,"completion":575,"start":576,"enrollment":577,"conditions":735,"interventions":736},[39],[579,580],[565,582,583,584,585,586,587,588,589,590,591,592],{"trials":738,"activeCount":50},[],{"trials":740,"activeCount":50},[],{"trials":742,"activeCount":50},[],{"trials":744,"activeCount":50},[],{"intervention":590,"totalTrials":46,"cells":746},{"EARLY_PHASE1":747,"PHASE1":749,"PHASE2":755,"PHASE3":757,"PHASE4":759,"NA":761},{"trials":748,"activeCount":50},[],{"trials":750,"activeCount":50},[751],{"nctId":572,"briefTitle":573,"status":100,"phases":752,"primaryCompletion":575,"completion":575,"start":576,"enrollment":577,"conditions":753,"interventions":754},[39],[579,580],[565,582,583,584,585,586,587,588,589,590,591,592],{"trials":756,"activeCount":50},[],{"trials":758,"activeCount":50},[],{"trials":760,"activeCount":50},[],{"trials":762,"activeCount":50},[],{"intervention":591,"totalTrials":46,"cells":764},{"EARLY_PHASE1":765,"PHASE1":767,"PHASE2":773,"PHASE3":775,"PHASE4":777,"NA":779},{"trials":766,"activeCount":50},[],{"trials":768,"activeCount":50},[769],{"nctId":572,"briefTitle":573,"status":100,"phases":770,"primaryCompletion":575,"completion":575,"start":576,"enrollment":577,"conditions":771,"interventions":772},[39],[579,580],[565,582,583,584,585,586,587,588,589,590,591,592],{"trials":774,"activeCount":50},[],{"trials":776,"activeCount":50},[],{"trials":778,"activeCount":50},[],{"trials":780,"activeCount":50},[],{"intervention":592,"totalTrials":46,"cells":782},{"EARLY_PHASE1":783,"PHASE1":785,"PHASE2":791,"PHASE3":793,"PHASE4":795,"NA":797},{"trials":784,"activeCount":50},[],{"trials":786,"activeCount":50},[787],{"nctId":572,"briefTitle":573,"status":100,"phases":788,"primaryCompletion":575,"completion":575,"start":576,"enrollment":577,"conditions":789,"interventions":790},[39],[579,580],[565,582,583,584,585,586,587,588,589,590,591,592],{"trials":792,"activeCount":50},[],{"trials":794,"activeCount":50},[],{"trials":796,"activeCount":50},[],{"trials":798,"activeCount":50},[],{"intervention":419,"totalTrials":46,"cells":800},{"EARLY_PHASE1":801,"PHASE1":803,"PHASE2":809,"PHASE3":811,"PHASE4":813,"NA":815},{"trials":802,"activeCount":50},[],{"trials":804,"activeCount":50},[805],{"nctId":411,"briefTitle":412,"status":100,"phases":806,"primaryCompletion":414,"completion":414,"start":415,"enrollment":416,"conditions":807,"interventions":808},[39],[20],[394,419,420],{"trials":810,"activeCount":50},[],{"trials":812,"activeCount":50},[],{"trials":814,"activeCount":50},[],{"trials":816,"activeCount":50},[],{"intervention":420,"totalTrials":46,"cells":818},{"EARLY_PHASE1":819,"PHASE1":821,"PHASE2":827,"PHASE3":829,"PHASE4":831,"NA":833},{"trials":820,"activeCount":50},[],{"trials":822,"activeCount":50},[823],{"nctId":411,"briefTitle":412,"status":100,"phases":824,"primaryCompletion":414,"completion":414,"start":415,"enrollment":416,"conditions":825,"interventions":826},[39],[20],[394,419,420],{"trials":828,"activeCount":50},[],{"trials":830,"activeCount":50},[],{"trials":832,"activeCount":50},[],{"trials":834,"activeCount":50},[],{"intervention":836,"totalTrials":46,"cells":837},"ticagrelor",{"EARLY_PHASE1":838,"PHASE1":840,"PHASE2":855,"PHASE3":857,"PHASE4":859,"NA":861},{"trials":839,"activeCount":50},[],{"trials":841,"activeCount":50},[842],{"nctId":843,"briefTitle":844,"status":100,"phases":845,"primaryCompletion":846,"completion":846,"start":847,"enrollment":848,"conditions":849,"interventions":854},"NCT01883869","Targeting Platelet-Leukocyte Aggregates in Pneumonia With Ticagrelor",[39],"2016-06","2013-06",60,[850,851,852,853],"Pneumonia","Community Acquired Pneumonia","Hospital Acquired Pneumonia","Acute Lung Injury",[836],{"trials":856,"activeCount":50},[],{"trials":858,"activeCount":50},[],{"trials":860,"activeCount":50},[],{"trials":862,"activeCount":50},[],{"intervention":864,"totalTrials":46,"cells":865},"Methylphenidate",{"EARLY_PHASE1":866,"PHASE1":868,"PHASE2":880,"PHASE3":882,"PHASE4":884,"NA":886},{"trials":867,"activeCount":50},[],{"trials":869,"activeCount":50},[870],{"nctId":871,"briefTitle":872,"status":100,"phases":873,"primaryCompletion":874,"completion":874,"start":875,"enrollment":876,"conditions":877,"interventions":878},"NCT02700711","Methylphenidate-Duloxetine Combinations for Cocaine Dependence",[39],"2018-06","2016-02",13,[20],[864,879],"Duloxetine",{"trials":881,"activeCount":50},[],{"trials":883,"activeCount":50},[],{"trials":885,"activeCount":50},[],{"trials":887,"activeCount":50},[],{"intervention":879,"totalTrials":46,"cells":889},{"EARLY_PHASE1":890,"PHASE1":892,"PHASE2":898,"PHASE3":900,"PHASE4":902,"NA":904},{"trials":891,"activeCount":50},[],{"trials":893,"activeCount":50},[894],{"nctId":871,"briefTitle":872,"status":100,"phases":895,"primaryCompletion":874,"completion":874,"start":875,"enrollment":876,"conditions":896,"interventions":897},[39],[20],[864,879],{"trials":899,"activeCount":50},[],{"trials":901,"activeCount":50},[],{"trials":903,"activeCount":50},[],{"trials":905,"activeCount":50},[],{"intervention":407,"totalTrials":46,"cells":907},{"EARLY_PHASE1":908,"PHASE1":914,"PHASE2":916,"PHASE3":918,"PHASE4":920,"NA":922},{"trials":909,"activeCount":50},[910],{"nctId":399,"briefTitle":400,"status":100,"phases":911,"primaryCompletion":402,"completion":402,"start":403,"enrollment":57,"conditions":912,"interventions":913},[38],[405,28],[394,407],{"trials":915,"activeCount":50},[],{"trials":917,"activeCount":50},[],{"trials":919,"activeCount":50},[],{"trials":921,"activeCount":50},[],{"trials":923,"activeCount":50},[],{"intervention":925,"totalTrials":46,"cells":926},"Zortress® \u002FEverolimus",{"EARLY_PHASE1":927,"PHASE1":929,"PHASE2":931,"PHASE3":933,"PHASE4":935,"NA":937},{"trials":928,"activeCount":50},[],{"trials":930,"activeCount":50},[],{"trials":932,"activeCount":50},[],{"trials":934,"activeCount":50},[],{"trials":936,"activeCount":50},[],{"trials":938,"activeCount":50},[939],{"nctId":940,"briefTitle":941,"status":211,"phases":942,"primaryCompletion":943,"completion":943,"start":944,"enrollment":50,"conditions":945,"interventions":947},"NCT01612299","Effects of Zortress® + Tacrolimus vs. Standard Immunosuppression on Progression of Coronary Artery Calcifications and Bone Disease in de Novo Renal Transplant Recipients",[43],"2013-12","2012-05",[946],"Renal Transplant",[925],{"intervention":949,"totalTrials":46,"cells":950},"Cevimeline",{"EARLY_PHASE1":951,"PHASE1":953,"PHASE2":955,"PHASE3":957,"PHASE4":959,"NA":961},{"trials":952,"activeCount":50},[],{"trials":954,"activeCount":50},[],{"trials":956,"activeCount":50},[],{"trials":958,"activeCount":50},[],{"trials":960,"activeCount":50},[],{"trials":962,"activeCount":50},[963],{"nctId":964,"briefTitle":965,"status":100,"phases":966,"primaryCompletion":967,"completion":256,"start":968,"enrollment":57,"conditions":969,"interventions":971},"NCT01690052","Efficacy of Cevimeline Versus Pilocarpine in the Secretion of Saliva",[43],"2010-06","2009-01",[970],"Dry Mouth",[949,972],"Pilocarpine",{"intervention":972,"totalTrials":46,"cells":974},{"EARLY_PHASE1":975,"PHASE1":977,"PHASE2":979,"PHASE3":981,"PHASE4":983,"NA":985},{"trials":976,"activeCount":50},[],{"trials":978,"activeCount":50},[],{"trials":980,"activeCount":50},[],{"trials":982,"activeCount":50},[],{"trials":984,"activeCount":50},[],{"trials":986,"activeCount":50},[987],{"nctId":964,"briefTitle":965,"status":100,"phases":988,"primaryCompletion":967,"completion":256,"start":968,"enrollment":57,"conditions":989,"interventions":990},[43],[970],[949,972]]